AbCellera utilizes advanced computational biology and engineering to discover and develop antibody-based therapeutics for conditions with high unmet medical needs. The company aims to enhance patient outcomes by efficiently translating scientific discoveries into clinical applications.
Funding
$515.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional antibody discovery methods often struggle with complex targets, low hit rates, and inefficient lead optimization, resulting in delays and increased costs in developing effective antibody-based therapeutics. Many promising drug targets, particularly complex transmembrane proteins, remain inaccessible to conventional antibody discovery approaches.
Solution
AbCellera is a biotechnology company focused on developing antibody-based therapies by integrating advanced technologies across computation, engineering, and biology. The company leverages a single-cell screening platform to deeply search natural immune responses and identify rare, potent antibodies against challenging disease targets. By combining high-throughput screening, microfluidics, machine learning, and protein engineering, AbCellera aims to accelerate the discovery and development of differentiated antibody therapeutics. Their integrated platform spans from target selection and antibody discovery to preclinical development and clinical manufacturing, enabling efficient progression of candidates towards clinical studies.
Target Audience
AbCellera's primary focus is on developing its own pipeline of antibody therapeutics for unmet medical needs, with a focus on autoimmunity, endocrine and metabolic conditions, and oncology.
Features
- Proprietary single-cell screening technology for identifying rare and diverse antibodies
- High-throughput microfluidic devices for isolating and screening thousands of single cells
- Advanced immunization strategies for eliciting robust immune responses against difficult targets
- Capabilities for generating and characterizing recombinant soluble and membrane proteins
- Protein engineering capabilities for optimizing antibody sequences and formats, including bispecifics and T-cell engagers
- In-house clinical manufacturing facility for GMP cell banking and drug substance production
- Integrated computational tools and machine learning models for antibody selection and optimization